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Abstract: Treatment with ultrasound and microbubbles (sonoporation) to enhance therapeutic
efficacy in cancer therapy is rapidly expanding, but there is still very little consensus as to why it
works. Despite the original assumption that pore formation in the cell membrane is responsible for
increased uptake of drugs, the molecular mechanisms behind this phenomenon are largely unknown.
We treated cancer cells (MOLM-13) and healthy peripheral blood mononuclear cells (PBMCs) with
ultrasound at three acoustic intensities (74, 501, 2079 mW/cm2) ±microbubbles. We subsequently
monitored the intracellular response of a number of key signaling pathways using flow cytometry or
western blotting 5 min, 30 min and 2 h post-treatment. This was complemented by studies on uptake
of a cell impermeable dye (calcein) and investigations of cell viability (cell count, Hoechst staining
and colony forming assay). Ultrasound + microbubbles resulted in both early changes (p38 (Arcsinh
ratio at high ultrasound + microbubbles: +0.5), ERK1/2 (+0.7), CREB (+1.3), STAT3 (+0.7) and AKT
(+0.5)) and late changes (ribosomal protein S6 (Arcsinh ratio at low ultrasound: +0.6) and eIF2α in
protein phosphorylation). Observed changes in protein phosphorylation corresponded to changes in
sonoporation efficiency and in viability, predominantly in cancer cells. Sonoporation induced protein
phosphorylation in healthy cells was pronounced (p38 (+0.03), ERK1/2 (−0.03), CREB (+0.0), STAT3
(−0.1) and AKT (+0.04) and S6 (+0.2)). This supports the hypothesis that sonoporation may enhance
therapeutic efficacy of cancer treatment, without causing damage to healthy cells.
Keywords: sonoporation; microbubbles; ultrasound; intracellular signaling; phosphorylation;
ultrasound contrast agents; drug delivery; cellular stress
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1. Introduction
The use of microbubbles (MB), such as ultrasound contrast agents, together with ultrasound (US) to
improve therapeutic efficacy has a multitude of applications, ranging from enhancing drug penetration
through tissue, opening of the blood brain barrier, to sonothrombolysis [1]. The term “sonoporation”
has been commonly used to describe the formation of pores in cells using US + MB, derived from the
term “electroporation”, and is commonly used to describe the pore formation phenomenon observed
in cell culture experiments. The therapeutic effects of US + MB enhanced therapy have shown great
potential over the last 20 years. It can be used to increase the delivery and resulting efficacy of drugs
and is therefore particularly useful in cancer therapy, where poor uptake of drugs is one of the factors
limiting therapeutic effect [2]. The therapeutic benefits of US + MB enhanced therapy in cancer have
been demonstrated in numerous preclinical trials [3–6]. Furthermore, a Phase I clinical trial [7] showed
that US + MB enhanced therapy in combination with chemotherapy is safe and may increase survival
of patients suffering from pancreatic ductal adenocarcinoma, and is being followed by clinical trials in
other cancers [8–10].
Numerous in vitro studies have demonstrated that the combined use of ultrasound and
microbubbles forms pores in the membranes of cancer cells [11]. The improved chemotherapeutic
efficacy was subsequently assumed to be due to passive diffusion of the drugs through the pores.
Nevertheless, despite substantial research in this field, it is not fully understood if the mechanical
stresses induced by the microbubbles contribute to additional molecular mechanisms. It has been
suggested that cellular stress induced by sonoporation may contribute to the enhancement of cancer
therapy [12]. These additional therapeutic effects, which are induced by the biophysical stimuli of
the microbubbles interacting with cells, must involve activation of intracellular signaling pathways.
However, it is still not known how protein phosphorylation in intracellular signaling pathways changes
in response to sonoporation. Low intensity ultrasound used to accelerate bone and joint healing,
has been found to induce integrin/mechanotransduction signaling that include proteins like p38,
ERK1/2 and JNK (Mitogen-activated protein (MAP)-kinase pathway) and focal adhesion kinase (FAK),
in chondrocytes [13] and synovial cells [14]. Additionally, low intensity ultrasound has been described
to stimulate cell growth though the integrin/FAK/phosphoinositide-3-kinase-protein kinase (PI3K)
pathway, including Akt, in chondrocytes [15] and osteoblasts [16]. As sonoporation also includes the
use of microbubbles, knowledge on how addition of microbubbles influences the cellular responses is
needed. In respect to the clinical application of this approach, it would further be of great importance
to understand how sonoporation influences different cell types. Specifically, to contrast the effects
induced on cancer cells or healthy cells, of which both will inevitably be exposed during cancer therapy.
To gain more insight into the molecular mechanisms of sonoporation, our aim was to analyze
phosphorylation changes in intracellular signaling networks following treatment with ultrasound with
and without the addition of microbubbles. Uptake of a cell impermeable dye and cell viability assays
were used to determine the efficacy of sonoporation. We have investigated the intracellular signaling
responses of increasing ultrasound intensity and addition of microbubbles using two commercially
available ultrasound contrast agents in both a cancer cell line and healthy peripheral blood mononuclear
cells (PBMCs).
2. Materials and Methods
2.1. Chemicals
All chemicals were purchased from Merck KGaA (Darmstadt, Germany) unless otherwise stated.
2.2. Microbubbles
SonazoidTM (GE Healthcare, Little Chalfont, UK) was reconstituted by adding 2 mL NaCl 9 mg/mL
(Fresenius Kabi, Bad Homburg vor der Höhe, Germany) and gently agitating for 30 s. The bubbles
were aspirated via a 19 G needle, and a 19 G venting needle was used to avoid a pressure drop in
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the vial. Bubbles were diluted in NaCl 9 mg/mL immediately before addition to cells. SonoVue®
(Bracco S.p.A., Milan, Italy) was prepared following manufacturer specifications. To ensure that the
reconstituted bubbles were stable, Sonazoid™ bubbles were used within 1 h of reconstitution, and
SonoVue® bubbles within 30 min.
2.3. Cell Culture
The leukemic cell-line MOLM-13 (DSMZ, Braunschweig, Germany) was cultured in RPMI
1640 medium supplemented with 10% fetal bovine serum and 1% l-glutamine. Peripheral blood
mononuclear cells (PBMCs) were isolated from concentrated leukocyte suspensions of healthy donors,
generated from whole blood by centrifugation. Blood was supplied from healthy volunteers, from
the Department of Immunology at Haukeland University Hospital, Bergen, Norway. PBMCs were
isolated using density gradient separation (LymphoprepTM, Abbott Laboratories, Chicago, IL, USA),
followed by red blood cell lysis performed in Red Cell lysis buffer (155 mM NH4Cl, 10 mM NaHCO3,
0.1 mM EDTA and distilled water). PBMCs were cultured in RPMI 1640 supplemented with 10% FBS
and 1% l-glutamine. All cells were cultured in a 5% CO2 humidified atmosphere at 37 ◦C.
2.4. In Vitro Treatment with Ultrasound and Microbubbles
MOLM-13 cell suspension was seeded into six wells of a 24-well plate (TPP Techno Plastic Products
AG, Trasadingen, Switzerland). A total of 1 × 106 cells/well in 2.5 mL supplemented RPMI 1640
culture media were seeded (0.4 × 106 cells/mL) and rested for approximately 1–2 h prior to sonication.
The MOLM-13 cell line was exposed to ultrasound whilst in exponential growth. The PBMCs were
treated directly following separation from blood. A total of 8 × 106 cells/well in 2.5 mL supplemented
RPMI 1640 culture media (3.2 × 106 cell/mL) were seeded and rested for approximately 30–60 min
prior to sonication. As MOLM-13 cells are larger than PBMC cells, the PMBC cell concentration was
increased to match the total cell volume of the MOLM-13 experiments (Figure S1). Microbubbles
were added at a final concentration of 0.4 × 106 bubbles/mL (1 × 106 bubbles per well), based on an a
priori dose-response study (Figure S2). This microbubble dose correlates to a clinical dose of 1.7 mL
of SonazoidTM, and 10.0 mL of SonoVue®. Both doses are above clinical imaging and diagnostic
recommendations from the manufactures. Immediately following bubble addition, a self-adhering
membrane (TopSeal™–A, Perkin Elmer, Waltham, MA, USA) was stuck on the top surface of the
24-well plate to create a watertight seal. This membrane was used as the acoustic propagation interface
and the acoustic amplitude was compensated for the membrane attenuation (measured to be <1% at
1.0 MHz). The plate was inverted, placed in the ultrasound treatment chamber [17] and ultrasound
was applied. Figure 1 shows a schematic of the ultrasound treatment chamber. In short, the ultrasound
chamber consisted of 6 single element, unfocused, disc transducers (PZ26, 2 mm thickness, 15 mm
diameter). A 3D printed chamber was used to accurately align the transducers and 6 wells within
the 24 well plate. The center of the water volume in the cell culture wells was aligned with the axial
acoustic focus. Three different US conditions were used (Table 1), referred to as “Low”, “Medium”,
or “High”. All samples were sonicated for 10 min. In all experiments the Mechanical Index (MI) was
kept below 0.4, which is generally considered safe [18]. Only the “High” acoustic condition was above
the clinical diagnostic imaging guidelines in terms of the ISPTA value. Nevertheless, much higher
values are already used in therapeutic ultrasound clinical trials.
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and subsequently analyzed using an Accuri C6 flow cytometer (BDBioscience, Franklin Lakes, NJ, 
USA). Incubation time was evaluated prior to experiments (Figure S3). A duration of 40 min or more 
was required due experimental feasibility constraints. An incubation time of 60 min was chosen as 
this was an indicated pore re-sealing time [19]. A minimum of three replicates were analyzed per 
experiment, and all experiments were performed three times. 
2.6. Viability Analysis 
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samples were harvested for both viability assays and studies on intracellular signaling. Cell 
concentration was determined by manual counting using a haemocytometer. This was done 
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Low 1.108 4 4 10 0.2 74 0.66
Medium 1.108 18 16 10 0.3 501 2.31
High 1.108 41 37 10 0.4 2079 5.0
2.5. Uptake of Cell Impermeable Dye
To measure sonoporation efficiency calcein, a non-toxic, ll impermeable fluorescent dye, was
added during treatment with ultrasoun ± icrobubbles. Calc in was d ssolved in 1 M NaOH
to a stock solutio of 50 g/mL and protected from light at 2–8 ◦C. For each xperi e t, a fresh
solution of 2.5 mg/mL in 9 mg/mL NaCl (Fresenius K bi, Bad Homburg vor der Höhe, Germany)
was prepared. Calcein was added to the cell suspension to a concentration of 5 µM immediately
before sonication. After ultrasound treatment, the cells were incubated for 40–60 min, washed twice in
PBS, and subsequently analyzed using an Accuri C6 flow cytometer (BDBioscience, Franklin Lakes,
NJ, USA). Incubation time was evaluated prior to experiments (Figure S3). A duration of 40 min or
more was required due experimental feasibility constraints. An incubation time of 60 min was chosen
as this was an indicated pore re-sealing time [19]. A minimum of three replicates were analyzed per
experiment, and all experiments were performed three times.
2.6. Viability Analysis
In separate experiments without calcein, cells were treated with ultrasound ± microbubbles
and samples were harvested for both viability assays and studies on intracellular signaling. Cell
concentration was determined by manual counting using a haemocytometer. This was done
immediately after treatment with ultrasound and after 24 h of culture. Apoptotic cell death was
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assessed by adding 0.01 mg/mL Hoechst 33342 (Merck KGaA, Darmstadt, Germany) to cells after
24 h of culturing. Cells were fixed in 4% formaldehyde and imaged by fluorescence microscopy.
The total number of cells was determined in Fiji [20] by adjusting the image brightness and contrast
followed by a manual threshold then using the “Analyze particles” function. Apoptotic cells were
counted manually using the “Cell counter” plugin in Fiji. Colony forming assay (Methocult™ Classic
H4434; Stemcell™ Technologies, Vancouver, BC, Canada) was used to evaluate the proliferation of
the MOLM-13 cells. Cells were seeded immediately after treatment and colonies were counted after
7–10 days incubation. All experiments were performed in triplicate.
2.7. Sample Preparation for Phosphospecific Flow Cytometry
Samples for intracellular signaling studies were taken at three different time points: immediately
after sonoporation (approximately 5 min), after 30 min, and 2 h of incubation. Cells were fixed by
adding 16% paraformaldehyde (Alfa Aesar, Haverhill, MA, USA) to a final concentration of 2% and
incubating for 15 min at room temperature, washed in cold PBS and permeabilized in ice-cold methanol,
following a modified protocol [21,22]. As positive controls for intracellular signaling, MOLM-13 cells
were treated with either 1 µM A23187 (Calcimycin; calcium ionophore) for 4 h, 100 ng/mL TNF-α for
15 min, or 1 µM A23187 + 100 nM phorbol myristate acetate (PMA; PKC activator) for 30 min. PBMCs
were treated with 1 µM A23187 + 100 nM PMA for 30 min as positive control. Variation in response to
A23187 + PMA between cells from 3 different donors and MOLM-13 are shown in Figure S6.
2.8. Barcoding and Antibody Staining
Fluorescent cell barcoding was used to perform multiplex flow cytometry. Individual cell samples
were stained with unique signatures of succimidylesters of Pacific Blue (0.05 µg/mL, 0.5 µg/mL,
5 µg/mL) and Pacific Orange (0 µg/mL, 2.5 µg/mL and 20 µg/mL). After barcode staining, the samples
were pooled prior to antibody staining [23]. A graphical depiction of barcoding/sample preparation for
phospho-flow cytometry is shown in Figure S4. One barcode represents all samples from one timepoint
in each experiment. Barcoded cells were split into staining panels and each panel was stained separately
with a combination of antibodies conjugated to either Alexa Fluor® 488 or 647 (Table S1). PBMC samples
were incubated with FcR-blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) prior to
antibody staining. Samples were analyzed on an LSR Fortessa flow cytometer (BDBioscience, Franklin
Lakes, NJ, USA). After flow cytometric analysis the samples were de-barcoded and the arcinhratio for
each treated sample to the untreated cells, harvested at the same timepoint, was calculated.
2.9. Western Blots
Samples for western blot were harvested 2 h post sonoporation, washed twice in PBS and lysed in
RIPA buffer containing protease- and phosphatase inhibitor (Thermo Fisher Scientific, Waltham, MA,
USA). Protein concentration was quantified in accordance with Bio-Rad DC protein assay instruction
manual for microtiter plates. For the western blots 10% SDS-polyacrylamide gels were loaded with
20–30 µg protein per well. Proteins were separated at 100–120 V and transferred to a nitrocellulose
membrane (240 mA, 150 min, 4 ◦C), followed by 1 h blocking using 5% skim milk powder in Tris-buffered
saline (TBS) + 1% Tween 20. Primary antibodies were diluted in 5% skim milk in TBS-Tween and
incubated over night at 4 ◦C. Primary antibodies used were p-eIF2α Ser-51 (Abcam, Cambridge, UK)
and eIF2α (Abcam). COX IV (Abcam) was used as loading control. Secondary antibodies were diluted
in 5% skim milk powder in TBS-Tween 20 and incubated for 1 h at room temperature. Membranes were
developed using SuperSignal® West Pico or SuperSignal® West Femto Chemiluminescence Substrate
(Thermo Fischer Scientific) in accordance with manufacturers recommendations.
2.10. Data Analysis/Statistical Analysis
Data collected from the Accuri C6 flow cytometer was analyzed in FlowJo® (BDBioscience,
Franklin Lakes, NJ, USA). Data collected from LSR Fortessa on barcoded samples were de-barcoded
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and gated in FlowJo®. Gating strategy is shown in Supplemental Figure S5. Further analysis was
performed in Cytobank (Cytobank Inc., Santa Clara, CA, USA). Arcsinh ratio (arcsinh(treated/5)-
arcsinh(control/5)) was used to calculate changes in phosphorylation. Statistical comparisons were
performed in Prism 6 (GraphPad Software, San Diego, CA, USA) using unpaired two-tailed t-tests.
Significance level was set at p-value 0.05. All p-values are shown in Tables S2–S6.
3. Results
3.1. Efficiency of Sonoporation Was Increased by Addition of Microbubbles and High Ultrasound Intensity
3.1.1. Percentage of Cells Taking Up Calcein (Permeabilization Efficiency)
We investigated sonoporation efficiency by measuring uptake of the cell impermeable dye calcein
into the cells, a measure of cell permeabilization. Figure 2 shows the percentage of cells positive
for calcein after ultrasound treatment ±microbubbles. Increasing ultrasound intensity increased the
percentage of calcein-positive cells (Figure 2a,b). In the absence of microbubbles, only high ultrasound
intensity induced a significant increase in calcein-positive MOLM-13 cells. The addition of either
SonoVue® or Sonazoid™microbubbles resulted in a significantly increased number of calcein-positive
cells at medium or high ultrasound intensity (No bubbles: 1.5% and 1.5%; SonoVue®: 6.4% and 29%;
Sonazoid™: 14% and 35%, at medium and high ultrasound respectively) (Figure 2a, Tables S2 and S3).
Sonazoid™ induced a significantly higher percentage of calcein-positive cells than SonoVue® (Table S4)
and based on these results we used Sonazoid™ for subsequent experiments. In PBMCs, the addition of
Sonazoid™ increased the number of calcein-positive cells to 6% at medium ultrasound and to 20% at
high ultrasound intensity, while no significant difference was observed without the use of microbubbles
(Figure 2b). Figure 2c compares the efficacy of each ultrasound condition + Sonazoid™ for MOLM-13
cells and PBMCs. At medium and high ultrasound intensities, a significantly larger population of the
MOLM-13 cells vs. PBMCs were calcein-positive (Table S5).
Pharmaceutics 2019, 11, 319 7 of 17
Pharmaceutics 2019, 11, x 7 of 19 
 
 
Figure 2. Increasing the ultrasound intensity and the addition of microbubbles significantly 
increased the percentage of calcein-positive cells. (a) Percentage of calcein-positive MOLM-13 cells 
versus ultrasound intensity. Increasing the ultrasound intensity correlated to an increase in calcein 
positive cells. The addition of microbubbles significantly increased the calcein-positive population. 
At medium and high ultrasound intensities Sonazoid™ was significantly better than SonoVue®. (b) 
Percentage of calcein positive peripheral blood mononuclear cells (PBMCs) versus ultrasound 
intensity. Ultrasound alone did not increase the calcein-positive population. The addition of 
Sonazoid™ significantly increased the calcein-positive population at medium and high ultrasound 
intensities. (c) Comparison of calcein-positive population between MOLM-13 cells and PBMCs. At 
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The median fluorescence intensity (MFI) was used as an estimate of calcein uptake and is 
depicted as fold change of controls not treated with ultrasound or microbubbles (Figure 3). As for 
the percentage of calcein-positive cells (Figure 2c) the effect of increasing ultrasound intensity alone 
was only significant at high ultrasound intensity, while the addition of microbubbles increased 
calcein uptake at all ultrasound intensities in MOLM-13 cells (Figure 3a, Tables S2 and S3). The 
uptake enhancement by using Sonazoid™ vs. SonoVue® was confirmed (SonoVue®: 8-fold and 
14-fold increase at increase at medium and high ultrasound intensity respectively; Sonazoid™: 
12-fold and 22-fold) at all three ultrasound intensities (Table S4). In PBMCs a significant increase in 
calcein uptake was observed at medium and high ultrasound intensity + Sonazoid™ (Figure 3b). The 
Figure 2. Increasing the ultrasound intensity and the addition of microbubbles significantly increased
the percentage of calcein-positive cells. (a) Percentage of calcein-positive MOLM-13 cells versus
ultrasound intensity. Increasing the ultrasound intensity correlated to an increase in calcein positive
cells. The addition of microb bbles sig ificantly increased the cal ein-positive population. At medium
and high ultrasound intensities Sonazoid™ was significa tly better than SonoVue®. (b) Percentage of
calcein positive peripheral blood mononuclear cells (PBMCs) versus ultrasound intensity. Ultrasound
alone did not increase the calcein-positive population. The addition of Sonazoid™ significantly
increased the calcein-positive population at medium and high ultrasound intensities. (c) Comparison
of calcein-positive population between MOLM-13 cells and PBMCs. At medium and high ultrasound
intensities a significantly larger population of the MOLM-13 cells were calcein positive. * = p < 0.05,
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 (Significance depicted for Sonazoid™ vs. SonoVue®, and
MOLM-13 vs. PBMC. All p-values can be found in Tables S2–S5).
3.1.2. Quantified Uptake of Calcein
The median fluorescence intensity (MFI) was us d as an estimate of calcei uptake and is
depicted as fold change of controls not treated with ultrasound or microbubbles (Figure 3). As for
the percentage of calcein-positive cells (Figure 2c) the effect of increasing ultrasound intensity alone
was only signific nt at high ultrasound intensity, while the addition of microbubbles incr ased calcein
uptake at ll ultrasound intensities in MOLM-13 cells (Figure 3a, Tables S2 and S3). The uptake
enhancement by using Sonazoid™ vs. SonoVue® was confirmed (SonoVue®: 8-fold and 14-fold
increase at increase at medium and high ultrasound intensity respectively; Sonazoid™: 12-fold and
22-fold) at all three ultrasound intensities (Table S4). In PBMCs a significant increase in calcein uptake
was observed at medium and high ultrasound intensity + Sonazoid™ (Figure 3b). The uptake was
significantly higher in MOLM-13 cells than PBMCs at all 3 ultrasound intensities (Figure 3c, Table S5).
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forces lead to any immediate cell damages from the treatment. Cell lysis or immediate necrosis was 
only observed at much higher acoustic intensities than those evaluated in this study, (i.e., MI = 0.6, 
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Figure 3. Sonoporation induced significant increase in uptake of model drug calcein in sonoporated
cells measured by median fluorescence intensity. (a) Fold change of medi n fluor scence intensity
(MFI) in MOLM-13 cells affected by sonoporation (=calcein-positive cells). The increase in calcein
uptake depended on addition of microbubbles and ultrasound intensity. Use of Sonazoid resulted in
significantly higher increase in uptake than SonoVue at all three ultr sound intensities. (b) Fold change
of median fluorescence intensity (MFI) in calcein-positive PBMC. The uptake is significantly dependent
on addition of microbubbles and ultrasound intensity (significant increase in uptake nly seen at high
ultrasound intensity). (c) Comparison of calcein uptake between MOLM-13 and PBMC. A significantly
higher percentage of cancerous MOLM-13 cells were affected than healthy PBMC at all 3 ultrasound
intensities. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 (Significance depicted for Sonazoid™ vs.
SonoVue®, and MOLM-13 vs. PBMC. All p-values can be found in Tables S2–S5).
3.2. Decreased Viability in Cancerous MOLM-13 Cells after Sonoporation
The cell count was measured immediately after sonoporation to determine if the mechanical
forces lead to any immediate cell damages from the treatment. Cell lysis or immediate necrosis was
only observed at much higher acoustic intensities than those evaluated in this study, (i.e., MI = 0.6,
ISPTA = 2673mW/cm2, Duty Cycle = 20%). No significant changes in total cell counts were observed
for either MOLM-13 or PBMCs at any of the ultrasound intensities when compared to controls not
treated with ultrasound (Figure 4a,d, Tables S2 and S3). However, a small increase in cell count was
observed using low ultrasound without microbubbles at both 0 and 24 h compared to untreated cells.
After 24 h a significantly lower cell count was observed in MOLM-13 cells treated with medium and
high ultrasound with the addition of microbubbles (Figure 4b, Tables S2 and S3). In PBMCs a modest,
but statistically significant, decrease in cell count after 24 h was observed at medium ultrasound with
microbubbles (p < 0.05) (94% and 99% cells relative to untreated cells, respectively). To elucidate if the
reduced cell count of MOLM-13 was a result of increased cell death or reduced proliferative ability,
Hoechst 33342 staining and colony forming assay were performed. The addition of microbubbles
and application of medium or high US increased the percentage of apoptotic MOLM-13 cells to 6%
and 13% respectively (Figure 4c, Tables S2 and S3). Upon Hoechst staining of PBMCs, no significant
change in apoptotic cells was observed at any treatment regime. Colony forming assays (Figure 4d,
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Tables S2 and S3) demonstrated that MOLM-13 cells formed significantly less colonies at medium and







Figure 4. Viability of cells in response to ultrasound ± SonazoidTM microbubbles (a) Normalized cell
count at different ultrasound intensities ± SonazoidTM microbubbles (normalized to cells not treated
with ultrasound), of cells harvested immediately after sonoporation (0 h). No significant change in
cell count due to sonoporation was observed (b) Normalized cell count of cells harvested 24 h after
sonoporation. After 24 h the cell count was significantly lower in samples treated with medium
(p < 0.05) and high (p < 0.05) ultrasound intensity. The cell count of PBMCs did not change much after
24 h in any of the samples. A small increase in cell count was observed in the samples treated with
the lowest ultrasound intensity, but this effect is not significant. A small, but significant, decrease in
cell count was observed in the sample treated with medium ultrasound intensity. (c) Apoptotic cells
24 h post sonoporation by Hoechst 33342 staining in MOLM-13 and PBMC (d) Number of colonies
of MOLM-13 formed post sonoporation (colony forming assay). * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.001.
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3.3. Sonoporation Induced Changes in Intracellular Signaling-Profiles
In line with the results observed from calcein uptake experiments (Figures 2 and 3) the changes
in intracellular signaling were more pronounced in MOLM-13 cells (Figure 5a) compared to PBMCs
(Figure 5b). Significantly increased signaling was observed at medium and high ultrasound intensity
and when microbubbles were added during sonication (Figure 5a, Table S6). Increased phosphorylation
from untreated cells was observed for p-38 T180/Y182, ERK1/2 T202/Y204, CREB S133/ATF-1, Akt S473
and STAT3 S727 in the MOLM-13 cell line. Sonoporation altered STAT3 phosphorylation specifically at
the Ser727 epitope, and there was no change in phosphorylation status on the Tyr 705 epitope. STAT5
phosphorylation level was not affected by sonoporation. Phosphorylation status of FAK, NF-kB, Src,
PDPK1 or p53 did not change.
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5 min, 30 min and 2 h post sonoporation (mean of Arcsinh ratios) (b) Heatmaps displaying changes
in phosphorylation status in PBMC f the ch sen range of proteins in respons to treatment with
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3.3.1. Immediate Effects of Sonoporation
Changes in intracellular signaling b oporation in MOLM-13 were m stly observed
immediately after treatment (Figure 5a). Phosphorylation of p38 T180/Y182, ERK1/2 T202/Y204,
Akt S473, and STAT3 S727 (Figure 6a, Table S5) was significantly increased 5 min after sonoporation.
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Phosphorylation generally decayed rapidly and the difference from controls was either lower or not
detected 30 min after sonoporation. Changes in phosphorylation were primarily observed when cells
were treated with medium and high ultrasound intensity with microbubbles. Only phosphorylation
of p38 was significantly increased without microbubbles, and only at high ultrasound intensity.
A significant increase in phosphorylation immediately after sonoporation with microbubbles was also
observed for CREB S133/ATF-1. However, this was sustained for a longer time period. Phosphorylation
of CREB S133/ATF-1 was significant increased for up to 2 h when using medium or high US +
MB (Figure 6b, Table S5). Furthermore, the changes in phosphorylation of p38 T180/Y182, ERK1/2
T202/Y204, CREB S133/ATF-1, Akt S473 and STAT3 S727 are predominantly seen when increasing
ultrasound from low to medium intensity (+ microbubbles). No significant differences were found
when increasing from medium to high ultrasound intensity (Figure 6, Table S6).
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Figure 6. Significant changes in phosphor l served for p38, ERK1/2, CREB, Akt and
STA 3 (S727) in MOL -13 cells. The incr ases in phosphorylation primarily occurred when increasing
ultrasound from low to medium. (a) Scatter plots of results 5 min post sonoporation from 3 individual
experiments. Phosphorylation status of p38, ERK1/2, Akt and STAT3 (S727) were transiently altered
from untreated controls at medium and high ultrasound intensity in the presence of microbubbles.
(b) Scatter plots of results at 5 min, 30 min and 2 h from 3 individual experiments. Phosphorylation
status of CREB was altered by sonoporation for up to 2 h. * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.001 (Significance depicted for Low ultrasound vs. Medium ultrasound. All p-values can be
found in Tables S2–S5).
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3.3.2. Downstream Effects of Sonoporation—Ribosomal Protein S6
Not all the effects of sonoporation on intracellular signaling were observed immediately after
treatment. A difference in phosphorylation status of ribosomal protein S6, specifically on the S235/236
epitope, was seen 2 h after sonoporation (Figure 7). At high ultrasound, phosphorylation was
lower than at the lower ultrasound intensities and in particular at high ultrasound with addition of
microbubbles there is almost no difference in phosphorylation compared to untreated controls. At low
and medium ultrasound intensity the phosphorylation is higher than untreated controls both with
and without microbubbles. A similar yet very weak response was also detected in PBMCs (Figure 5b).
However, none of the observed changes in phosphorylation of ribosomal protein S6 were statistically
significant. No changes from untreated controls in phosphorylation were observed at the S240 epitope
on ribosomal protein S6.
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3.3.3. Downstream Effects of Sonoporation—Eukaryotic Initiation Factor 2α
Eukaryotic initiation factor 2 alpha (eIF2α) signaling may have an inverse relationship to mTOR/S6
signaling [24], and to elucidate the downstream mechanism the phosphorylation status of eIF2α was
investigated. The Western blot in Figure 8 shows that eIF2α was ph sphoryla ed 2 h post sonoporation
in MOLM-13 when exposed to medium and high ultrasound intensity with addition of microbubbles.
The phosphorylation of eIF2α was increasing from medium to high ultrasound (+ microbubbles).
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4. Discussion
In this study we present a new insight in the cellular responses following sonoporation, by an
extensive screen of phosphorylation changes in intracellular signaling pathways. Although a range of
bioeffects in response to sonoporation is already known [25,26], the intracellular signaling responses
have so far been overlooked. We found that sonoporation activates key signaling pathways, such as the
MAP-kinase pathway and PI3K-pathway, and both transcription and translation factors. The use of our
high-throughput ultrasound treatment chamber [17] enabled us to relate these new findings with more
commonly used measures of sonoporation efficiency: uptake of a cell-impermeable dye [19,27–31]
(permeabilization) and cell viability [19,27,31–33]. Interestingly, there is a shift in the phosphorylation
profile of the cells at the acoustic/microbubble conditions in which calcein uptake is increased and
viability is decreased, and this trend corresponds with increasing ultrasound intensity and was
significantly enhanced by addition of microbubbles during US treatment. The results on calcein uptake
and viability are in agreement with the existing literature, although an important observation is the
higher sensitivity to sonoporation of the cancerous MOLM-13 compared to healthy PBMCs. Also, in
the PBMCs, only minor changes in intracellular signaling are detected. The increased susceptibility
of cancer cells to ultrasound has previously been observed [34,35], and suggested to be a result of
different cell size, morphology or faster growth rate of cancer cells. While the MOLM-13 cells used in
this study are indeed larger in size than PBMCs (Figure S1) further work will be required to verify
this hypothesis.
Our calcein uptake experiments indicated that Sonazoid™microbubbles are more effective than
SonoVue® microbubbles at the chosen treatment conditions. Whilst both agents are lipid-shell based
they have different responses to ultrasound (e.g., different resonant frequencies), gas content, shell
stiffness, stability, size distribution, and polydispersity [36,37]. The improved effectiveness of Sonazoid™
could be due to any of these physicochemical properties or behaviors at the chosen ultrasound
parameters and concentrations. Changing the acoustic frequencies, concentration, or selecting a specific
bubble size population could result in SonoVue® or any other microbubble being more effective.
The effect of sonoporation on intracellular phosphorylation patterns in MOLM-13 can be divided
into immediate effects and more long-lasting effects. An immediate and transient increase of
phosphorylation was observed for proteins of the MAP-Kinase (ERK, p38) and PI3K (Akt) pathway.
Activation of p38, ERK and Akt by ultrasound alone was also observed in previous studies in other
cell types [13,14,16]. In contrast to our results, these previous studies showed increased cell growth.
The activation of these proteins is known to be involved in increased proliferation of cells, but the
broad range of effects of those proteins is not only limited to the regulation of cell growth and
differentiation. They also involve transmission of stress stimuli (p38 [38]), cell cycle regulation and
proliferation (ERK [39]) and cell survival (Akt [40]). We further observe an increase in phosphorylation
of transcription factors CREB and STAT3, which may be activated downstream of MAP-kinases [41–43].
For STAT3, this is supported by the fact that it is phosphorylated on the serine 727 epitope only,
and there is no change in phosphorylation status on the Tyr705 epitope which is phosphorylated
downstream of JAK in the JAK/STAT pathway [41,42].
The downstream effects of sonoporation in MOLM-13 that we have observed are changes in
phosphorylation of eIF2α and ribosomal protein S6. The phosphorylation of ribosomal protein S6,
specifically at the Ser235/236 epitope, followed the inverse trend of immediate signaling events, and
was induced by low and medium ultrasound ± microbubbles. This activation was not observed
when high ultrasound + microbubbles was used. Ribosomal protein S6 is linked to an increase in
cell growth whilst phosphorylation of eIF2α may reduce cell growth [24]. Both eIF2α and ribosomal
protein S6 are involved in protein translation, the final step in expression of genes into proteins and
a part of biosynthesis that is tightly connected to cell growth. Therefore, these signaling events are
in line with our observed decrease in viability at the higher ultrasound plus microbubble conditions.
Phosphorylation of eIF2α inhibit general protein translation and cell proliferation in response to
cellular stresses, among them endoplasmatic reticulum (ER-) stress—a known bioeffect in response to
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sonoporation [33]. Activation of ribosomal protein S6 Ser235/236, on the other hand, may simulate
cap-dependent protein translation, downstream of ERK [44]. The observed signaling events suggest
that sonoporation may influence protein translation.
These results, performed on the same validated experimental platform, indicate that sonoporation
may in fact induce both signals, promoting and decreasing viability of cells, depending on ultrasound
intensity and the addition of microbubbles. In clinical use, ultrasound parameters, microbubbles and
drugs must be chosen carefully, and protein phosphorylation can potentially be used as biomarkers to
guide the choice of therapeutic parameters. Furthermore, a reason that the sonoporation mechanisms
are still debated is the diversity of experimental parameters, experimental systems and cell types used
in the in vitro studies [25,45]. This study also highlights that differences in ultrasound parameters and
treatment of different cell types may result in variable, maybe even opposing, biological responses.
Throughout this study, an increase in acoustic intensity induced increased responses. This increased
intensity was achieved by increasing both the number of acoustic cycles, i.e., the duty cycle, and
peak-negative acoustic pressure, which makes it impossible to correlate the effects specifically to
an increase in either MI or duty cycle. Due to thermal and design limitations in the experimental
setup, it was not possible to use a single MI value or duty cycle to achieve the given range of acoustic
intensities. Further work should be performed to determine which of the two parameters is more
critical. Nevertheless, taking into account that microbubble stability is very low after 10–20 continuous
ultrasound cycles, we can conjecture that the MI is the dominant factor and a similar response could be
observed at clinically relevant acoustic intensities.
Whilst the results in this study signify that each cell type may respond differently to the same
treatment conditions, it is important to note that this work was performed in an in vitro configuration
that does not accurately mimic the human physiology. Specifically, this experimental configuration
used hard plastics that results in acoustic aberrations, there was no flow or temperature and gas
saturation regulation, the treatment fluids had a different viscosity to blood, and they were performed
in a large open chamber instead of vessel mimicking setup. To validate the results, these experiments
should be repeated in a more physiologically relevant model. It should also be noted that even though
ultrasound enhanced therapies has been suggested for leukemia [46], the main focus is on solid tumors
and the repeated experiments should be performed using cell types constituting solid tumors.
5. Conclusions
Our results show that the treatment with ultrasound and microbubbles alone affect viability and
intracellular signaling in cells, and this may be relevant for the efficacy of sonoporation to enhance
cancer therapy. The cancerous MOLM-13 cells were more susceptible to sonoporation when compared
to the healthy blood cells. Ultrasound alone at clinical diagnostic conditions had no significant
effect on cell permeabilization, cell viability, or intracellular protein phosphorylation. The addition
of microbubbles, or surpassing clinical diagnostic intensities resulted in increased permeabilization
efficiency, reduced cell viability and a change in phosphorylation status of p38, ERK1/2, CREB, Akt,
STAT3, ribosomal protein S6 and eIF2α in the cancer cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/7/319/s1,
Figure S1: Volume normalisation of cell concentration. Figure S2: (a) Percentage calcein-positive cells by increasing
concentration of SonazoidTM (b) Calcein uptake (fold change of mean fluorescence intensity) of cells by increasing
concentration of SonazoidTM. Figure S3: Optimisation of incubation time post treatment (n = 1). Increasing the
incubation time results in minor increases in the number of calcein positive cells. Figure S4: Sample processing
for phospho-flow cytometry. After sonoporation cells were fixed and permeabilised, barcoded, stained with
phosphorylation specific antibodies and analysed by flow cytometry. Barcoding of cells allows for reduced
analytical variation. Samples harvested after 5 min, 30 min and 2 h after sonoporation at low medium and
high ultrasound intensity were barcoded and pooled in to one sample per timepoint. All treated samples were
normalized to untreated cells in the same barcode. Pooled samples were divided in tubes for antibody staining
with panels consisting of 2 phosphospecific antibodies conjugated to respectively Alexa 488 and Alexa 647.
Figure S5: Gating strategy of flow cytometric data. After identification of the populations the median fluorescence
intensity of each sample of cells treated with ultrasound ±microbubbles was compared to the median fluorescence
intensity of the untreated cells. Figure S6: Change in phosphorylation status in response to positive controls
Pharmaceutics 2019, 11, 319 15 of 17
(A23187 + PMA), represented as arcinhratio normalised to untreated cells. Some variation in response is observed
between peripheral blood mononuclear cells (PBMC) from 3 different donors. PBMCs exhibit a stronger reponse
to this stimuli compared to cell line MOLM-13. Table S1: Phospho-proteins investigated using flow cytometry.
Table S2: The effect of increasing ultrasound intensity on uptake of calcein and viability (Ultrasound treatment vs
untreated sample). Table S3: The effect of adding microbubbles on uptake of calcein and viability (Treatment
without microbubbles vs treatment with microbubbles). Table S4: The effect of using different bubbles on calcein
uptake (SonoVue® vs SonazoidTM). Table S5: The different response in different cell types on calcein uptake
(MOLM-13 vs PBMCs). Table S6: The effect of increasing ultrasound intensity and microbubbles on protein
phosphorylation (Ultrasound treatment vs untreated sample). Table S7: The effect of increasing ultrasound
intensity protein phosphorylation (Ultrasound treatment X vs Ultrasound treatment Y).
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